• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前哨淋巴结阴性的II期黑色素瘤患者的肿瘤有丝分裂率及其与复发的关联

Tumor Mitotic Rate and Association with Recurrence in Sentinel Lymph Node Negative Stage II Melanoma Patients.

作者信息

Laks Shachar, Meyers Michael O, Deal Allison M, Frank Jill S, Stitzenberg Karyn B, Yeh Jen Jen, Thomas Nancy E, Ollila David W

出版信息

Am Surg. 2017 Sep 1;83(9):972-978.

PMID:28958277
Abstract

Tumor mitotic rate (TMR) is a known prognostic variable in thin melanoma patients. Its significance in stage II melanoma patients is yet to be demonstrated. Retrospective analysis of a prospective melanoma database from 9/1997 to 7/2015 was performed. All stage II melanoma, with documented TMR, and six months of follow-up were included. We evaluated the association of clinicopathologic variables, TMR, as a continuous and categorical variable with recurrence-free survival (RFS) and overall survival (OS) using Cox proportional hazards modeling. We used a statistical model, X-tile, to develop optimal categorizations of TMR. A total of 265 patient characteristics are included in this study. Recurrences occurred in 82 (30.9%) patients, including 5 local, 41 regional, and 36 distant patients. In multivariate model, ulceration, Breslow, and continuous TMR were associated with worse RFS\OS. Continuous TMR demonstrated worse RFS (hazards ratio [HR] 1.02 (1.00-1.05)) and OS (HR 1.02 (1.00-1.04)), whereas dichotomized TMR (≥1 vs <1) was not significant. TMR >10.4 mitoses/mm2 has a 5-year RFS\OS of 27.2 and 44.3 per cent, respectively, compared with 57.4 and 71.4 per cent, respectively, for TMR <3.2 mitoses/mm2. Continuous TMR predicts incidence of recurrence in stage II melanoma. We propose a new categorization method developed by statistical modeling for optimal stratification that may guide surveillance for this disparate patient population.

摘要

肿瘤有丝分裂率(TMR)是薄型黑色素瘤患者已知的预后变量。其在II期黑色素瘤患者中的意义尚待证实。对1997年9月至2015年7月的前瞻性黑色素瘤数据库进行了回顾性分析。纳入了所有有记录TMR且随访6个月的II期黑色素瘤患者。我们使用Cox比例风险模型评估了临床病理变量、作为连续和分类变量的TMR与无复发生存期(RFS)和总生存期(OS)之间的关联。我们使用一种统计模型X-tile来制定TMR的最佳分类。本研究共纳入265例患者特征。82例(30.9%)患者出现复发,包括5例局部复发、41例区域复发和36例远处复发。在多变量模型中,溃疡、Breslow厚度和连续TMR与较差的RFS/OS相关。连续TMR显示较差的RFS(风险比[HR]1.02(1.00 - 1.05))和OS(HR 1.02(1.00 - 1.04)),而二分法TMR(≥1 vs <1)无显著性差异。与TMR <3.2个有丝分裂/平方毫米时分别为57.4%和71.4%相比,TMR>10.4个有丝分裂/平方毫米时5年RFS/OS分别为27.2%和44.3%。连续TMR可预测II期黑色素瘤的复发发生率。我们提出一种通过统计建模开发的新分类方法,用于最佳分层,这可能会指导对这一不同患者群体的监测。

相似文献

1
Tumor Mitotic Rate and Association with Recurrence in Sentinel Lymph Node Negative Stage II Melanoma Patients.前哨淋巴结阴性的II期黑色素瘤患者的肿瘤有丝分裂率及其与复发的关联
Am Surg. 2017 Sep 1;83(9):972-978.
2
Tumor mitotic rate added to the equation: melanoma prognostic factors changed? : a single-institution database study on the prognostic value of tumor mitotic rate for sentinel lymph node status and survival of cutaneous melanoma patients.肿瘤有丝分裂率纳入方程:黑色素瘤预后因素改变了吗?:一项关于肿瘤有丝分裂率对皮肤黑色素瘤患者前哨淋巴结状态及生存预后价值的单机构数据库研究
Ann Surg Oncol. 2015 Sep;22(9):2978-87. doi: 10.1245/s10434-014-4349-3. Epub 2015 Jan 21.
3
Prognostic significance of tumor mitotic rate in T2 melanoma staged with sentinel lymphadenectomy.前哨淋巴结清扫分期为T2期黑色素瘤中肿瘤有丝分裂率的预后意义
J Surg Oncol. 2015 May;111(6):711-5. doi: 10.1002/jso.23880. Epub 2015 Feb 8.
4
The prognostic role of mitotic rate in cutaneous malignant melanoma: Evidence from a multicenter study on behalf of the Italian Melanoma Intergroup.有丝分裂率在皮肤恶性黑色素瘤中的预后作用:代表意大利黑色素瘤研究组的多中心研究证据。
Cancer. 2023 Aug 1;129(15):2331-2340. doi: 10.1002/cncr.34824. Epub 2023 May 10.
5
Sentinel lymph node biopsy in thick malignant melanoma: a 10-year single unit experience.前哨淋巴结活检在厚型恶性黑色素瘤中的应用:10 年单中心经验。
J Plast Reconstr Aesthet Surg. 2012 Oct;65(10):1396-402. doi: 10.1016/j.bjps.2012.04.019. Epub 2012 May 1.
6
Sentinel node status predicts survival in thick melanomas: the Oxford perspective.前哨淋巴结状态预测厚型黑色素瘤的生存情况:牛津的观点。
Eur J Surg Oncol. 2012 Oct;38(10):936-42. doi: 10.1016/j.ejso.2012.04.011. Epub 2012 May 20.
7
Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma.黑色素瘤前哨淋巴结活检及选择性淋巴结清扫术后的初始复发模式及预后
Plast Reconstr Surg. 2003 Aug;112(2):486-97. doi: 10.1097/01.PRS.0000070989.23469.1F.
8
Clinical impact of sentinel lymph node biopsy in patients with thick (>4 mm) melanomas.前哨淋巴结活检对厚度大于 4mm 的黑色素瘤患者的临床影响。
Am J Surg. 2014 May;207(5):702-7; discussion 707. doi: 10.1016/j.amjsurg.2013.12.022. Epub 2014 Mar 19.
9
Worse outcome for patients with recurrent melanoma after negative sentinel lymph biopsy as compared to sentinel-positive patients.与前哨淋巴结阳性的黑色素瘤患者相比,前哨淋巴结活检阴性的复发性黑色素瘤患者预后更差。
Eur J Surg Oncol. 2016 Sep;42(9):1420-6. doi: 10.1016/j.ejso.2016.03.038. Epub 2016 Apr 19.
10
Prognostic factors in melanoma patients with tumor-negative sentinel lymph nodes.肿瘤阴性前哨淋巴结黑色素瘤患者的预后因素
Surgery. 2016 May;159(5):1412-21. doi: 10.1016/j.surg.2015.12.002. Epub 2016 Jan 8.

引用本文的文献

1
Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator.预测 II 期黑色素瘤患者的无复发生存和总生存:MIA 计算器。
J Clin Oncol. 2024 Apr 1;42(10):1169-1180. doi: 10.1200/JCO.23.01020. Epub 2024 Feb 5.
2
Prediction of early-stage melanoma recurrence using clinical and histopathologic features.利用临床和组织病理学特征预测早期黑色素瘤复发
NPJ Precis Oncol. 2022 Oct 31;6(1):79. doi: 10.1038/s41698-022-00321-4.
3
Genetic variants of SDCCAG8 and MAGI2 in mitosis-related pathway genes are independent predictors of cutaneous melanoma-specific survival.
有丝分裂相关通路基因 SDCCAG8 和 MAGI2 的遗传变异是皮肤黑色素瘤特异性生存的独立预测因子。
Cancer Sci. 2021 Oct;112(10):4355-4364. doi: 10.1111/cas.15102. Epub 2021 Aug 27.
4
Identification of gene expression levels in primary melanoma associated with clinically meaningful characteristics.鉴定原发性黑色素瘤中与具有临床意义的特征相关的基因表达水平。
Melanoma Res. 2018 Oct;28(5):380-389. doi: 10.1097/CMR.0000000000000473.